Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,634 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, Luo Z, Xia J, Zhou Y, Xu M, Liu E, Jiang G, Li S, Zhao F, Ma C, Ma C, Hou Z, Li J, Wang J, Wang F. Meng X, et al. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):245-253. doi: 10.1016/S2468-1253(21)00378-2. Epub 2022 Jan 6. Lancet Gastroenterol Hepatol. 2022. PMID: 34998471 Clinical Trial.
Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial.
Wu JW, Zhou CF, Han ZX, Zhang H, Yan J, Chen J, Wang CB, Qin ZQ, Mao Y, Tang XY, Zhu LJ, Wei XW, Cui DH, Yang XL, Shi M, Zhao LQ, Jiang JL, Zhu WY, Wang HM, Wang C, Zhu LJ, Zhang J. Wu JW, et al. Among authors: yang xl. Signal Transduct Target Ther. 2024 Dec 9;9(1):344. doi: 10.1038/s41392-024-02051-4. Signal Transduct Target Ther. 2024. PMID: 39648217 Free PMC article. Clinical Trial.
Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J, Wei B, Feng J, Wu X, Chang Y, Wang Y, Yang X, Zhang H, Han S, Zhang C, Zheng J, Groen HJM, van den Berg A, Ma J, Li H, Guo Y. Li J, et al. Front Endocrinol (Lausanne). 2022 Dec 13;13:1006480. doi: 10.3389/fendo.2022.1006480. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36583000 Free PMC article.
Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial.
He Z, Yang X, Ma T, Yang Q, Zhang C, Chen Y, Wang P, D'Incecco A, Metro G, Uematsu S, Wang Q. He Z, et al. Transl Lung Cancer Res. 2022 Aug;11(8):1657-1666. doi: 10.21037/tlcr-22-558. Transl Lung Cancer Res. 2022. PMID: 36090635 Free PMC article.
[Expert consensus on ethical requirements for artificial intelligence (AI) processing medical data].
Li C, Zhang XY, Wu YH, Yang XL, Yu HR, Jin HB, Li YB, Zhu ZH, Liu R, Liu N, Xie Y, Lyu LL, Zhu XH, Tang H, Li HF, Li HL, Zeng XJ, Chen ZX, Fan XF, Wang Y, Wu ZJ, Wu ZQ, Guan YQ, Xue MM, Luo B, Wang AM, Yang XW, Ying Y, Yang XH, Huang XZ, Lang MF, Chen SM, Zhang HH, Zhang Z, Huang W, Xu GB, Liu JQ, Song T, Xiao J, Xia YL, Guan YF, Zhu L. Li C, et al. Among authors: yang xl. Sheng Li Xue Bao. 2024 Dec 25;76(6):937-942. Sheng Li Xue Bao. 2024. PMID: 39780570 Free article. Review. Chinese.
1,634 results